MCID: GLC037
MIFTS: 59

Glucocorticoid Resistance

Categories: Genetic diseases, Rare diseases, Reproductive diseases, Endocrine diseases, Fetal diseases

Aliases & Classifications for Glucocorticoid Resistance

MalaCards integrated aliases for Glucocorticoid Resistance:

Name: Glucocorticoid Resistance 54 50 24 56 71
Cortisol Resistance from Glucocorticoid Receptor Defect 50 24 71
Glucocorticoid Receptor Deficiency 24 71 69
Glucocorticoid Resistance, Generalized 71 29
Cortisol Resistance 71 13
Gccr Deficiency 24 71
Gcr Deficiency 24 71
Grl Deficiency 24 71
Gccr 24 71
Chrousos Syndrome 71
Gcres 71

Characteristics:

Orphanet epidemiological data:

56
glucocorticoid resistance
Inheritance: Autosomal dominant,Autosomal recessive,Not applicable; Age of onset: All ages; Age of death: normal life expectancy;

OMIM:

54
Inheritance:
autosomal dominant


HPO:

32
glucocorticoid resistance:
Inheritance autosomal dominant inheritance


Classifications:



Summaries for Glucocorticoid Resistance

OMIM : 54
Generalized glucocorticoid resistance is an autosomal dominant disease characterized by increased plasma cortisol concentration and high urinary free cortisol, resistance to adrenal suppression by dexamethasone, and the absence of clinical stigmata of Cushing syndrome. The clinical expression of the disease is variable. Common features include hypoglycemia, hypertension, and metabolic alkalosis. In females, overproduction of adrenal androgens has been associated with infertility, male-pattern baldness, hirsutism, and menstrual irregularities. Other features include chronic fatigue and profound anxiety (summary by Chrousos et al., 1983; Donner et al., 2013). (615962)

MalaCards based summary : Glucocorticoid Resistance, also known as cortisol resistance from glucocorticoid receptor defect, is related to obsessive-compulsive personality disorder and keratosis, and has symptoms including hirsutism, acne and ambiguous genitalia. An important gene associated with Glucocorticoid Resistance is NR3C1 (Nuclear Receptor Subfamily 3 Group C Member 1), and among its related pathways/superpathways are PEDF Induced Signaling and Glucocorticoid receptor regulatory network. The drugs Prednisone and Celecoxib have been mentioned in the context of this disorder. Affiliated tissues include prostate, bone and t cells, and related phenotypes are Increased transferrin (TF) endocytosis and homeostasis/metabolism

UniProtKB/Swiss-Prot : 71 Glucocorticoid resistance: Hypertensive, hyperandrogenic disorder characterized by increased serum cortisol concentrations. Inheritance is autosomal dominant. Glucocorticoid resistance, generalized: An autosomal dominant disease characterized by increased plasma cortisol concentration and high urinary free cortisol, resistance to adrenal suppression by dexamethasone, and the absence of Cushing syndrome typical signs. Clinical features include hypoglycemia, hypertension, metabolic alkalosis, chronic fatigue and profound anxiety.

Related Diseases for Glucocorticoid Resistance

Diseases related to Glucocorticoid Resistance via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 81)
id Related Disease Score Top Affiliating Genes
1 obsessive-compulsive personality disorder 10.5 FKBP5 NR3C1
2 keratosis 10.4 FKBP5 NR3C1
3 hypoglycemic coma 10.3 IL2 NR3C1
4 leukemia 10.3
5 hypoaldosteronism, congenital, due to cmo ii deficiency 10.3 NR3C1 NR3C2
6 graft-versus-host disease, protection against 10.3 IL10 IL2
7 plantar wart 10.3 IL10 IL2
8 chronic graft versus host disease 10.3 IL10 IL2
9 trabecular follicular adenocarcinoma 10.3 NR3C1 NR3C2
10 cyclosporiasis 10.3 IL10 IL2
11 bronchiectasis 10.3 NR3C1 NR3C2
12 tularemia 10.3 IL10 IL2
13 north american indian childhood cirrhosis 10.3 NR3C1 NR3C2
14 hemophagocytic lymphohistiocytosis 10.3 IL10 IL2
15 acute monoblastic leukemia 10.2 IL10 IL2
16 orbital osteomyelitis 10.2 IL10 IL2
17 embryonal rhabdomyosarcoma 10.2 IL10 IL2
18 sezary's disease 10.2 IL10 IL2
19 lymphoblastic leukemia 10.2
20 ovarian endometrioid cystadenoma 10.2 IL10 IL2
21 adrenal cortex disease 10.2 NR3C1 NR3C2
22 abnormal retinal correspondence 10.2 IL10 IL2
23 esophagus melanoma 10.2 IL10 IL2
24 left bundle branch hemiblock 10.2 IL10 IL2
25 hereditary multiple exostoses 10.2 FKBP5 NR3C1
26 myelitis 10.2 IL10 IL2
27 heart sarcoma 10.1 IL10 IL2
28 gastric ulcer 10.1 IL10 IL2
29 acute interstitial pneumonia 10.1 IL10 IL2
30 bronchiectasis with or without elevated sweat chloride 1 10.1 NR3C1 NR3C2
31 opportunistic bacterial infectious disease 10.1 IL10 IL2
32 mucocutaneous leishmaniasis 10.0 IL10 IL2
33 asthma 10.0
34 blue toe syndrome 10.0 IL10 IL2
35 vallecula cancer 9.9 IL10 IL2 NR3C1
36 myopathy of extraocular muscle 9.9 FKBP5 NR3C1 NR3C2
37 mesenchymal cell neoplasm 9.9 IL10 IL2
38 lymphoma 9.8 IL10 IL2
39 rheumatoid arthritis 9.8
40 arthritis 9.8
41 thrombocytopenia 9.7
42 ulcerative colitis 9.7
43 inflammatory bowel disease 9.7
44 systemic lupus erythematosus 9.7
45 colitis 9.7
46 childhood leukemia 9.7
47 lupus erythematosus 9.7
48 hepatitis 9.6
49 multiple myeloma 9.6
50 acute lymphocytic leukemia 9.6

Graphical network of the top 20 diseases related to Glucocorticoid Resistance:



Diseases related to Glucocorticoid Resistance

Symptoms & Phenotypes for Glucocorticoid Resistance

Symptoms via clinical synopsis from OMIM:

54

Endocrine Features:
fatigue
hypoglycemia

Cardiovascular- Vascular:
hypertension

Metabolic Features:
metabolic alkalosis

Skin Nails & Hair- Hair:
male-pattern baldness (in some females)
hirsutism (in some females)

Laboratory- Abnormalities:
hypoglycemia
slightly elevated 24-hour mean plasma cortisol
increased urinary free cortisol

Neurologic- Behavioral Psychiatric Manifestations:
anxiety (in some patients)

Genitourinary- Internal Genitalia Female:
infertility (in some patients)
menstrual irregularities (in some patients)


Clinical features from OMIM:

615962

Human phenotypes related to Glucocorticoid Resistance:

56 32 (show all 25)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hirsutism 56 32 hallmark (90%) Very frequent (99-80%) HP:0001007
2 acne 56 32 frequent (33%) Frequent (79-30%) HP:0001061
3 ambiguous genitalia 56 32 occasional (7.5%) Occasional (29-5%) HP:0000062
4 fatigue 56 32 hallmark (90%) Very frequent (99-80%) HP:0012378
5 hypoglycemia 56 32 occasional (7.5%) Occasional (29-5%) HP:0001943
6 hypokalemia 56 32 frequent (33%) Frequent (79-30%) HP:0002900
7 infertility 56 32 occasional (7.5%) Occasional (29-5%) HP:0000789
8 hypertension 56 32 frequent (33%) Frequent (79-30%) HP:0000822
9 stroke 56 32 very rare (1%) Very rare (<4-1%) HP:0001297
10 oligospermia 56 32 occasional (7.5%) Occasional (29-5%) HP:0000798
11 oligomenorrhea 56 32 frequent (33%) Frequent (79-30%) HP:0000876
12 metabolic alkalosis 56 32 frequent (33%) Frequent (79-30%) HP:0200114
13 precocious puberty 56 32 occasional (7.5%) Occasional (29-5%) HP:0000826
14 adrenal hyperplasia 56 32 frequent (33%) Frequent (79-30%) HP:0008221
15 increased urinary cortisol level 56 32 hallmark (90%) Very frequent (99-80%) HP:0012030
16 female pseudohermaphroditism 56 32 occasional (7.5%) Occasional (29-5%) HP:0010458
17 decreased circulating aldosterone level 56 32 hallmark (90%) Very frequent (99-80%) HP:0004319
18 increased circulating acth level 56 32 hallmark (90%) Very frequent (99-80%) HP:0003154
19 increased circulating cortisol level 56 32 hallmark (90%) Very frequent (99-80%) HP:0003118
20 frontal balding 56 32 occasional (7.5%) Occasional (29-5%) HP:0002292
21 menstrual irregularities 32 occasional (7.5%) HP:0000858
22 anxiety 32 occasional (7.5%) HP:0000739
23 hypercortisolism 56 Occasional (29-5%)
24 abnormal testosterone level 56 Frequent (79-30%)
25 abnormal serum testosterone level 32 frequent (33%) HP:0030087

UMLS symptoms related to Glucocorticoid Resistance:


fatigue

GenomeRNAi Phenotypes related to Glucocorticoid Resistance according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased transferrin (TF) endocytosis GR00363-A 9.17 BCL2A1 FKBP5 IL10 IL2 MIF NR3C1

MGI Mouse Phenotypes related to Glucocorticoid Resistance:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.17 FKBP5 GRIP1 IL10 IL2 MIF NR3C1

Drugs & Therapeutics for Glucocorticoid Resistance

Drugs for Glucocorticoid Resistance (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 411)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 53-03-2 5865
2
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
3 Parecoxib Approved Phase 4 198470-84-7
4
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
5
Budesonide Approved Phase 4,Phase 3,Phase 2 51333-22-3 63006 5281004
6
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 83-43-2 6741
7
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 50-24-8 5755
8
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-02-2 5743
9
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 22916-47-8 4189
10
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 2 128794-94-5 5281078
11
Mycophenolic acid Approved Phase 4,Phase 2 24280-93-1 446541
12
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
13
Epinephrine Approved, Vet_approved Phase 4,Phase 2 51-43-4 5816
14
Mifepristone Approved, Investigational Phase 4,Phase 2,Phase 1 84371-65-3 55245
15 Racepinephrine Approved Phase 4,Phase 2
16
Eplerenone Approved Phase 4 107724-20-9 150310 443872
17
Spironolactone Approved Phase 4,Phase 2 1952-01-7, 52-01-7 5833
18
Cycloserine Approved Phase 4 68-41-7 401 6234
19
Ciprofloxacin Approved, Investigational Phase 4,Phase 3 85721-33-1 2764
20
Lenograstim Approved Phase 4,Phase 2,Phase 1 135968-09-1
21
Bisoprolol Approved Phase 4 66722-44-9 2405
22
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
23
Diphenhydramine Approved Phase 4 58-73-1, 147-24-0 3100
24
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
25
Granisetron Approved, Investigational Phase 4 109889-09-0 3510
26
Histamine Approved, Investigational Phase 4 75614-87-8, 51-45-6 774
27
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
28
Ondansetron Approved Phase 4 99614-02-5 4595
29
Promethazine Approved Phase 4 60-87-7 4927
30
Ranitidine Approved Phase 4 66357-59-3, 66357-35-5 3001055
31
Montelukast Approved Phase 4 158966-92-8 5281040
32
Bortezomib Approved, Investigational Phase 4,Phase 2,Phase 3 179324-69-7 387447 93860
33
Cyclophosphamide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 50-18-0, 6055-19-2 2907
34
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
35
Melphalan Approved Phase 4,Phase 2 148-82-3 4053 460612
36
Methotrexate Approved Phase 4,Phase 2,Phase 3,Phase 1 1959-05-2, 59-05-2 126941
37
rituximab Approved Phase 4,Phase 2,Phase 3 174722-31-7 10201696
38
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613 2171
39
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
40
Metronidazole Approved Phase 4,Phase 2 443-48-1 4173
41
Vancomycin Approved Phase 4 1404-90-6 441141 14969
42
Betamethasone Approved, Vet_approved Phase 4,Phase 3 378-44-9 9782
43
Desoximetasone Approved Phase 4 382-67-2 5311067
44
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
45
Dexmedetomidine Approved, Vet_approved Phase 4 76631-46-4, 113775-47-6 68602 5311068 56032
46
Itraconazole Approved, Investigational Phase 4,Phase 1,Phase 2 84625-61-6 55283
47
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 134070 5280453
48
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
49
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
50
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 59-30-3 6037

Interventional clinical trials:

(show top 50) (show all 264)

id Name Status NCT ID Phase Drugs
1 Steroids Pharmacokinetics and the Response to Prednisone Therapy in Giant Cell Arteritis Unknown status NCT01400464 Phase 4 Prednisone therapy and pharmacokinetic
2 Vitamin D for the Treatment of Severe Asthma Unknown status NCT00712205 Phase 4 Placebo;Calcitriol
3 Effect of COX-2 Selective Inhibitors on Postoperative Insulin Resistance After Gastrointestinal Laparoscopic Surgery Unknown status NCT01930318 Phase 4 parecoxib
4 Onset of Action of Advair Hydrofluoroalkane (HFA) 115/21 in Comparison to Symbicort Pressurised Metered-Dose Inhalers (pMDI) 160/4.5 Measured by Impulse Oscillometry (IOS) Unknown status NCT00867737 Phase 4 Advair HFA MDI 115/21;Symbicort 160/4.5 pMDI
5 Small Airways Evaluation and Treatment Unknown status NCT02526758 Phase 4 beclomethasone;formoterol;budesonide
6 Optimal Treatment of Plantar Fasciitis: Physical Training, Glucocorticoid Injections or a Combination Thereof. Completed NCT01994759 Phase 4 Glucocorticosteroid injection
7 Glucocorticoid Receptor Blockade With Mifepristone in Patients With Mild Adrenal Hypercortisolism Completed NCT01990560 Phase 4 Mifepristone
8 Safety and Efficacy of Oral Mega Pulse Methylprednisolone in Severe Therapy Resistant Alopecia Areata Completed NCT01167946 Phase 4 methylprednisolone sodium succinate;methylprednisolone sodium succinate;methylprednisolone sodium succinate
9 Reduction of Left Ventricular Hypertrophy After Eplerenone Therapy Completed NCT03186742 Phase 4 Eplerenone 50 mg Tab
10 Developing Memory Reconsolidation Blockers as Novel Posttraumatic Stress Disorder (PTSD) Treatments Completed NCT01490697 Phase 4 Mifepristone;d-Cycloserine;Placebo-matching Mifepristone;Placebo-matching d-Cycloserine (DCS)
11 Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer Completed NCT01649635 Phase 4 CABAZITAXEL (XRP6258);Prednisone;Ciprofloxacin;G-CSF (Granulocyte colony-stimulating factor)
12 Assess Particle Deposition and Acute Effects of Symbicort® Forte Turbohaler®) in COPD Patients. Completed NCT01329276 Phase 4 Symbicort® forte Turbohaler®
13 Dose-Response of Salmeterol in Children Completed NCT01907334 Phase 4 Advair Diskus100/50 µg;Flovent Diskus 100 µg;Methacholine Chloride;Albuterol
14 Chronic Obstructive Pulmonary Disease Endpoints Study Completed NCT00358358 Phase 4 Fluticasone Propionate/Salmeterol 500/50mcg combination;Fluticasone Propionate 500mcg;Salmeterol 50mcg
15 Beta Blocker Therapy in Moderate to Severe COPD Completed NCT01656005 Phase 4
16 Study Of Airway Physiology In Adults. SERETIDE DISKUS® Inhaler and FLIXOTIDE® Inhaler Are Trademarks of GSK Croup of Companies. Completed NCT00370591 Phase 4 Salmeterol/fluticasone propionate and fluticasone propionate
17 Study to Assess the Effect of Formoterol and Beclomethasone Dipropionate in Asthmatic Patients Completed NCT00910793 Phase 4 Inuvair
18 Combination of Cabazitaxel With Prednisolone With Primary Prophylaxis With PEG-G-CSF in Treatment of Patients With Prostate Cancer Completed NCT02441894 Phase 4 CABAZITAXEL XRP6258;PEG-G-CSF;Prednisolone;Dexchlorpheniramine or Diphenhydramine;Ranitidine;Metoclopramide, Granisetron, or Ondansetron;Dexamethasone
19 Effects of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease (COPD) Completed NCT00202189 Phase 4 Budesonide
20 Nebulized Beclomethasone Dipropionate Improves Respiratory Lung Function in Preschool Children With Recurrent Wheezing Completed NCT02381158 Phase 4 Nebulized beclomethasone dipropionate
21 Effect of Different Anti-Asthmatic Treatments on Lung Function and on Exercise-Induced Bronchoconstriction in Children With Asthma Completed NCT00490243 Phase 4 budesonide and montelukast;budesonide and formoterol;montelukast;budesonide;placebo
22 Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma Completed NCT00652041 Phase 4 Bortezomib;Thalidomide;Bortezomib
23 Achilles Tendinopathy Treated With Training and Injections Recruiting NCT02580630 Phase 4 Ultrasound guided injection with Glucocorticosteroid;Ultrasound guided injection with local anaestethic
24 Steroid Treatment for Hypereosinophilic Syndrome Recruiting NCT01524536 Phase 4 Corticosteroids
25 Rituximab (RTX) Therapy in Patients With Active TAO Recruiting NCT02378298 Phase 4 Rituximab;Iv Methylprednisolone;peroral methylprednisolone and Methotrexate
26 Adding Prednisolone During Ovulation Induction With CC in Lean Women With CC Resistant PCOS Recruiting NCT02344888 Phase 4 Clomiphene citrate and Prednisolone;Clomiphene citrate
27 Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent Recruiting NCT02485691 Phase 4 cabazitaxel XRP6258;enzalutamide;abiraterone acetate;prednisone
28 Manipulating the Microbiome in IBD by Antibiotics and FMT Recruiting NCT02033408 Phase 4 AB (antibiotics);CS (corticosteroids) Only
29 Effect of Antenatal Steroid on Pulmonary Artery Blood Flow Recruiting NCT02978976 Phase 4 Betamethasone;saline
30 Evaluating Treatment Resistant Dermatitis TaroIIR Active, not recruiting NCT03050294 Phase 4 Desoximetasone 0.25% spray
31 A Study of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Participants Who Responded Poorly to the First-line Combined Androgen Blockade Therapy Active, not recruiting NCT02405858 Phase 4 Abiraterone Acetate;Prednisolone
32 Safety Study of Continued Enzalutamide Treatment In Prostate Cancer Patients Active, not recruiting NCT01995513 Phase 4 Enzalutamide;Abiraterone;Placebo for Enzalutamide;Prednisone
33 Effects Of Adjuvants to Caudal Anesthesia on Hemodynamics Measured By Electrical Cardiometry In Children Enrolling by invitation NCT03101137 Phase 4 Caudal block with dexmedetomedine;Caudal dexamethasone;Control (bupivacaine)
34 Regulation of Insulin Secretion by the GLP-1 Receptor Not yet recruiting NCT02844907 Phase 4 Exendin (9-39);Dexamethasone
35 Evaluation of Antifungal Prophylaxis on Graft-versus-host Disease (GVHD) Patients Terminated NCT01282879 Phase 4 Itraconazole
36 ADVAIR DISKUS® (Fluticasone Propionate/Salmeterol) Inhaler Versus SEREVENT DISKUS® (Salmeterol) Inhlaer On Inflammatory Cells And Markers In Chronic Obstructive Pulmonary Disease. ADVAIR DISKUS® and SEREVENT DISKUS® Inhalers Are Trademarks of the GSK Grou Terminated NCT00346749 Phase 4 Salmeterol;Fluticasone Propionate/Salmeterol Combination Product
37 No Resistance After Long Term Treatment SERETIDE Withdrawn NCT00456313 Phase 4 FLIXOTIDE and SERETIDE
38 Post-marketing Surveillance Study on the Safety and Effectiveness of Abiraterone Acetate Among Adult Filipino Male Patients With Advanced Metastatic Castration Resistant Prostate Cancer Withdrawn NCT01692483 Phase 4 Abiraterone acetate;Prednisone
39 Prevention of Metabolic Complications of Glucocorticoid Excess Unknown status NCT01319994 Phase 2, Phase 3 Metformin;Placebo
40 Steroids in Patients With Early ARDS Unknown status NCT00562835 Phase 2, Phase 3 Methylprednisolone
41 Assessment of Insulin Sensitivity and β Cell Function by Clamps Studies Completed NCT02662400 Phase 2, Phase 3
42 Efficacy and Safety of Growth Hormone Treatment in Juvenile Idiopathic Arthritis Completed NCT00420251 Phase 3 Genotropin
43 Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100 Completed NCT01605227 Phase 3 cabozantinib;prednisone
44 Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer Completed NCT00988208 Phase 3 Lenalidomide;Docetaxel;Prednisone;Placebo
45 Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer Completed NCT00887198 Phase 3 Abiraterone acetate;Placebo;Prednisone
46 Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy Completed NCT00638690 Phase 3 Placebo;Abiraterone acetate;Prednisone/prednisolone
47 A Study of Abiraterone Acetate Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer Completed NCT01834209 Phase 3 Abiraterone acetate;Prednisone or prednisolone
48 Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Completed NCT01193257 Phase 3 Orteronel + prednisone;Placebo + prednisone
49 Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer Completed NCT01193244 Phase 3 Orteronel;Placebo;Prednisone
50 Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Completed NCT01308580 Phase 3 Cabazitaxel (XRP6258);Prednisone (or Prednisolone)

Search NIH Clinical Center for Glucocorticoid Resistance

Genetic Tests for Glucocorticoid Resistance

Genetic tests related to Glucocorticoid Resistance:

id Genetic test Affiliating Genes
1 Glucocorticoid Resistance, Generalized 29
2 Glucocorticoid Resistance 24 NR3C1

Anatomical Context for Glucocorticoid Resistance

MalaCards organs/tissues related to Glucocorticoid Resistance:

39
Prostate, Bone, T Cells, Lung, Pituitary, Liver, B Cells

Publications for Glucocorticoid Resistance

Articles related to Glucocorticoid Resistance:

(show top 50) (show all 255)
id Title Authors Year
1
Network-based expression analysis reveals key genes related to glucocorticoid resistance in infant acute lymphoblastic leukemia. ( 27798768 )
2017
2
JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias. ( 28484265 )
2017
3
Macrophage activation syndrome at the onset of glucocorticoid-resistant systemic lupus erythematosus: a case report. ( 28918421 )
2017
4
Why are depressed patients inflamed? A reflection on 20 years of research on depression, glucocorticoid resistance and inflammation. ( 28479211 )
2017
5
Glucocorticoid resistance as a major drive in sepsis pathology. ( 28479044 )
2017
6
Novel insights into the molecular mechanisms underlying generalized glucocorticoid resistance and hypersensitivity syndromes. ( 28742501 )
2017
7
Mechanisms of Brain Glucocorticoid Resistance in Stress-Induced Psychopathologies. ( 28320277 )
2017
8
MiR-124 contributes to glucocorticoid resistance in acute lymphoblastic leukemia by promoting proliferation, inhibiting apoptosis and targeting the glucocorticoid receptor. ( 28578002 )
2017
9
Glucocorticoid resistance of migration and gene expression in a daughter MDA-MB-231 breast tumour cell line selected for high metastatic potential. ( 28262792 )
2017
10
Low dose of 2-deoxy-D-glucose kills acute lymphoblastic leukemia cells and reverses glucocorticoid resistance via N-linked glycosylation inhibition under normoxia. ( 28415682 )
2017
11
Glucocorticoid resistance in chronic diseases. ( 27643454 )
2016
12
Prenatal SSRI alters the hormonal and behavioral responses to stress in female mice: Possible role for glucocorticoid resistance. ( 27283378 )
2016
13
Glucocorticoid resistance syndrome caused by two novel mutations in the NR3C1 gene. ( 27211791 )
2016
14
Runx1 Orchestrates Sphingolipid Metabolism and Glucocorticoid Resistance in Lymphomagenesis. ( 27869314 )
2016
15
Testicular Receptor-4: Novel Regulator of Glucocorticoid Resistance. ( 27253665 )
2016
16
Recent advances in the molecular mechanisms causing primary generalized glucocorticoid resistance. ( 27086682 )
2016
17
Relationship between expression of glucocorticoid receptor isoforms and glucocorticoid resistance in immune thrombocytopenia. ( 27077774 )
2016
18
Cytokine-Induced Glucocorticoid Resistance from Eosinophil Activation: Protein Phosphatase 5 Modulation of Glucocorticoid Receptor Phosphorylation and Signaling. ( 27742828 )
2016
19
Differential expression of GAS5 in rapamycin-induced reversion of glucocorticoid resistance. ( 27001230 )
2016
20
Janus and PI3-kinases mediate glucocorticoid resistance in activated chronic leukemia cells. ( 27579615 )
2016
21
Altered expression of autophagy-related genes might contribute to glucocorticoid resistance in precursor B-cell type acute lymphoblastic leukemia. ( 26947147 )
2016
22
Three Novel Heterozygous Point Mutations of NR3C1 causing Glucocorticoid Resistance. ( 27120390 )
2016
23
Inflammasome-mediated glucocorticoid resistance: The receptor rheostat. ( 27308575 )
2016
24
An emphasis on molecular mechanisms of anti-inflammatory effects and glucocorticoid resistance. ( 25503867 )
2015
25
Quantitative proteomic analysis reveals maturation as a mechanism underlying glucocorticoid resistance in B lineage ALL and re-sensitization by JNK inhibition. ( 26310606 )
2015
26
NALP3 inflammasome upregulation and CASP1 cleavage of the glucocorticoid receptor cause glucocorticoid resistance in leukemia cells. ( 25938942 )
2015
27
Glucocorticoid receptor polymorphisms: Lack of association with glucocorticoid resistance among Chinese bullous disease patients. ( 25894104 )
2015
28
The NLRP3-CASP1 Inflammasome Induces Glucocorticoid Resistance in ALL. ( 25977218 )
2015
29
MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia. ( 26324703 )
2015
30
Modulation of glucocorticoid resistance in pediatric T-cell Acute Lymphoblastic Leukemia by increasing BIM expression with the PI3K/mTOR inhibitor BEZ235. ( 26080839 )
2015
31
Targeting of the deubiquitinase USP9X attenuates B-cell acute lymphoblastic leukemia cell survival and overcomes glucocorticoid resistance. ( 25735983 )
2015
32
Changes of glucocorticoid receptor isoforms expression in acute lymphoblastic leukemia correlate with glucocorticoid resistance. ( 26062300 )
2015
33
Another step in understanding glucocorticoid resistance in critical illness. ( 26039432 )
2015
34
Inhibition of autophagy overcomes glucocorticoid resistance in lymphoid malignant cells. ( 25778879 )
2015
35
Thioimidazoline based compounds reverse glucocorticoid resistance in human acute lymphoblastic leukemia xenografts. ( 25967739 )
2015
36
Bortezomib Treatment can Overcome Glucocorticoid Resistance in Childhood B-cell Precursor Acute Lymphoblastic Leukemia Cell Lines. ( 25985447 )
2015
37
Tumor suppressor IKZF1 mediates glucocorticoid resistance in B-cell precursor acute lymphoblastic leukemia. ( 26713593 )
2015
38
Influence of glucocorticoid receptor gene NR3C1 646 C>G polymorphism on glucocorticoid resistance in asthmatics: a preliminary study. ( 26648776 )
2015
39
Piperlongumine inhibits the proliferation and survival of B-cell acute lymphoblastic leukemia cell lines irrespective of glucocorticoid resistance. ( 25193702 )
2014
40
Bioenergetic modulation overcomes glucocorticoid resistance in T-lineage acute lymphoblastic leukaemia. ( 24456076 )
2014
41
Lymphocyte sensitivity assay as a marker for glucocorticoid resistance in lupus: report of two sisters with systemic lupus erythematosus. ( 24285097 )
2014
42
Rheumatoid arthritis--a neuroendocrine immune disorder: glucocorticoid resistance, relative glucocorticoid deficiency, low-dose glucocorticoid therapy, and insulin resistance. ( 25611004 )
2014
43
Loss of TBL1XR1 disrupts glucocorticoid receptor recruitment to chromatin and results in glucocorticoid resistance in a B-lymphoblastic leukemia model. ( 24895125 )
2014
44
A novel point mutation of the human glucocorticoid receptor gene causes primary generalized glucocorticoid resistance through impaired interaction with the LXXLL motif of the p160 coactivators: dissociation of the transactivating and transreppressive activities. ( 24483153 )
2014
45
Molecular Mechanisms of Repeated Social Defeat-Induced Glucocorticoid Resistance: Role of microRNA. ( 25317829 )
2014
46
Multi-agent chemotherapy overcomes glucocorticoid resistance conferred by a BIM deletion polymorphism in pediatric acute lymphoblastic leukemia. ( 25090024 )
2014
47
Glucocorticoid resistance in dialysis patients reduces long-term graft survival after kidney transplantation. ( 24746801 )
2014
48
Role of human papillomaviruses in persistent and glucocorticoid-resistant juvenile phimosis. ( 22471970 )
2013
49
PPARI+ and fatty acid oxidation mediate glucocorticoid resistance in chronic lymphocytic leukemia. ( 23814018 )
2013
50
Immune dysregulation and glucocorticoid resistance in minority and low income pregnant women. ( 23541234 )
2013

Variations for Glucocorticoid Resistance

UniProtKB/Swiss-Prot genetic disease variations for Glucocorticoid Resistance:

71 (show all 12)
id Symbol AA change Variation ID SNP ID
1 NR3C1 p.Asp641Val VAR_004676 rs104893908
2 NR3C1 p.Val729Ile VAR_004677
3 NR3C1 p.Arg477His VAR_013472 rs104893913
4 NR3C1 p.Gly679Ser VAR_013473 rs104893914
5 NR3C1 p.Ile559Asn VAR_015632 rs104893909
6 NR3C1 p.Ile747Met VAR_015633 rs104893910
7 NR3C1 p.Phe737Leu VAR_071935 rs121909727
8 NR3C1 p.Leu773Pro VAR_071936 rs104893912
9 NR3C1 p.Thr556Ile VAR_075800
10 NR3C1 p.Arg477Ser VAR_077143
11 NR3C1 p.Tyr478Cys VAR_077144
12 NR3C1 p.Leu672Pro VAR_077145

ClinVar genetic disease variations for Glucocorticoid Resistance:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 NR3C1 NM_001018077.1(NR3C1): c.1922A> T (p.Asp641Val) single nucleotide variant Pathogenic rs104893908 GRCh37 Chromosome 5, 142675126: 142675126
2 NR3C1 NM_000176.2(NR3C1): c.1891_1892+2delGAGT deletion Pathogenic rs587776832 GRCh38 Chromosome 5, 143298666: 143298669
3 NR3C1 NM_001018077.1(NR3C1): c.1676T> A (p.Ile559Asn) single nucleotide variant Pathogenic rs104893909 GRCh37 Chromosome 5, 142680121: 142680121
4 NR3C1 NM_001018077.1(NR3C1): c.2241T> G (p.Ile747Met) single nucleotide variant Pathogenic rs104893910 GRCh37 Chromosome 5, 142661547: 142661547
5 NR3C1 NM_001018077.1(NR3C1): c.2318T> C (p.Leu773Pro) single nucleotide variant Pathogenic rs104893912 GRCh37 Chromosome 5, 142661470: 142661470
6 NR3C1 NM_001018077.1(NR3C1): c.1430G> A (p.Arg477His) single nucleotide variant Pathogenic rs104893913 GRCh37 Chromosome 5, 142689700: 142689700
7 NR3C1 NM_001018077.1(NR3C1): c.2035G> A (p.Gly679Ser) single nucleotide variant Pathogenic rs104893914 GRCh37 Chromosome 5, 142662279: 142662279
8 NR3C1 NM_001018077.1(NR3C1): c.2209T> C (p.Phe737Leu) single nucleotide variant Pathogenic rs121909727 GRCh37 Chromosome 5, 142661579: 142661579

Expression for Glucocorticoid Resistance

Search GEO for disease gene expression data for Glucocorticoid Resistance.

Pathways for Glucocorticoid Resistance

GO Terms for Glucocorticoid Resistance

Biological processes related to Glucocorticoid Resistance according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 steroid hormone mediated signaling pathway GO:0043401 9.32 NR3C1 NR3C2
2 positive regulation of B cell proliferation GO:0030890 9.26 IL2 MIF
3 positive regulation of cytokine secretion GO:0050715 8.96 IL10 MIF
4 negative regulation of apoptotic process GO:0043066 8.92 BCL2A1 IL10 IL2 MIF
5 extrinsic apoptotic signaling pathway in absence of ligand GO:0097192 8.85 IL2

Molecular functions related to Glucocorticoid Resistance according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 steroid hormone receptor activity GO:0003707 9.16 NR3C1 NR3C2
2 cytokine activity GO:0005125 9.13 IL10 IL2 MIF
3 steroid binding GO:0005496 8.62 NR3C1 NR3C2

Sources for Glucocorticoid Resistance

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....